Evaluation of patritumab/paclitaxel/trastuzumab over standard paclitaxel/trastuzumab in early stage, high-risk HER2 positive breast cancer: Results from the neoadjuvant I-SPY 2 trial

被引：0

作者：

Helsten, Teresa L. ^{[1
]}

Lo, Shelly S. ^{[2
]}

Yau, Christina ^{[3
]}

Kalinsky, Kevin ^{[4
]}

Elias, Anthony D. ^{[5
]}

Wallace, Anne M. ^{[1
]}

Chien, A. Jo ^{[3
]}

Lu, Janice ^{[6
]}

Lang, Julie E. ^{[6
]}

Albain, Kathy S. ^{[2
]}

Stringer-Reasor, Erica ^{[7
]}

Clark, Amy S. ^{[8
]}

Boughey, Judy C. ^{[9
]}

Ellis, Erin D. ^{[10
]}

Yee, Douglas ^{[11
]}

DeMichele, Angela ^{[8
]}

Isaacs, Claudine ^{[12
]}

Perlmutter, Jane ^{[13
]}

Rugo, Hope S. ^{[3
]}

Schwab, Richard ^{[1
]}

Hylton, Nola M. ^{[3
]}

Symmans, W. Fraser ^{[14
]}

Melisko, Michelle E. ^{[15
]}

van't Veer, Laura J. ^{[3
]}

Wilson, Amy ^{[16
]}

Singhrao, Ruby ^{[3
]}

Asare, Smita M. ^{[16
]}

Sanil, Ashish ^{[17
]}

Berry, Donald A. ^{[14
]}

Esserman, Laura J. ^{[3
]}

机构：

[1] Univ Calif San Diego, La Jolla, CA 92093 USA

[2] Loyola Univ, Maywood, IL 60153 USA

[3] Univ Calif San Francisco, San Francisco, CA 94143 USA

[4] Columbia Univ, New York, NY USA

[5] Univ Colorado, Aurora, CO USA

[6] Univ Southern Calif, Los Angeles, CA 90007 USA

[7] Univ Alabama Birmingham, Birmingham, AL USA

[8] Univ Penn, Philadelphia, PA USA

[9] Mayo Clin, Rochester, MN USA

[10] Swedish Canc Inst, Seattle, WA USA

[11] Univ Minnesota, Masonic Canc Ctr, Minneapolis, MN USA

[12] Georgetown Univ, Washington, DC USA

[13] Gemini Grp, Ann Arbor, MI USA

[14] Univ Texas MD Anderson Canc Ctr, Houston, TX USA

[15] Univ Calif San Francisco, La Jolla, CA USA

[16] Quantum Leap Healthcare Collaborat, San Francisco, CA USA

[17] Berry Consultants LLC, Austin, TX USA

来源：

CANCER RESEARCH | 2020年 / 80卷 / 04期

关键词：

D O I：

10.1158/1538-7445.SABCS19-P3-11-02

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P3-11-02

引用

页数：4

共 50 条

[41] I-SPY 2: a Neoadjuvant Adaptive Clinical Trial Designed to Improve Outcomes in High-Risk Breast Cancer
Haiyun Wang
Douglas Yee
[J]. Current Breast Cancer Reports, 2019, 11 : 303 - 310
[42] Efficacy and tolerability of neoadjuvant Pertuzumab, Trastuzumab, and weekly Paclitaxel in Locally advanced Her-2 positive Breast cancer
Gupta, Niraj
Giblin, Erica
Spivey, Tara
Govert, Kristen
Leagre, Christopher
Liebross, Robert
Tumati, Vasu
Dugan, Thomas
Yadav, Rina
Henman, Patrick
Beaudrie, Nick
Bair, Tessa
Durk, Jessica
Hancock, Marjaorie
Engle, Trisha
Myers, Michelle
Schneiders, Julie
Tigges, Thomas
[J]. CANCER RESEARCH, 2021, 81 (04)
[43] Phase I trial of ruxolitinib in combination with trastuzumab in metastatic HER2 positive breast cancer
Mundi, P. S.
Lee, S.
Chi, D.
Bhardwaj, A.
Makower, D.
Cigler, T.
Crew, K. D.
Hershman, D. L.
Califano, A.
Silva, J.
Kalinsky, K. M.
[J]. CANCER RESEARCH, 2017, 77
[44] Neoadjuvant bevacizumab (B) and trastuzumab (T) in combination with weekly paclitaxel (P) as neoadjuvant treatment in HER2-positive breast cancer: Results from a phase II trial (AVANTHER)
Fernandez Abad, Maria
Calvo, Isabel
Martinez, Noelia
Herrero, Mercedes
Quijano, Yolanda
Duran, Hipolito
Garcia Aranda, Mariola
Suarez, Ana
Lopez-Rios, Fernando
Perez, Diego
Perea, Sofia
Hidalgo, Manuel
Garca-Estevez, Laura
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
[45] Neoadjuvant therapy with FEC followed by weekly paclitaxel and concurrent trastuzumab in Her2 positive non operable breast cancer: a phase II study
Levaggi, A.
Poggio, F.
Lambertini, M.
D'Alonzo, A.
Giraudi, S.
Bighin, C.
Blondeaux, E.
Pastorino, S.
Abate, A.
Iacono, G.
Vaglica, M.
Conte, B.
Pronzato, P.
Del Mastro, L.
[J]. ANNALS OF ONCOLOGY, 2016, 27
[46] Weekly paclitaxel, trastuzumab, carboplatin is a highly effective neoadjuvant regimen in HER2-positive breast cancer: Results from the TRAIN-study
van Ramshorst, M. S.
van Werkhoven, E.
Mandjes, I. A. M.
Schot, M.
Wesseling, J.
Peeters, M-JTFD Vrancken
Rodenhuis, S.
Oosterkamp, H. M.
Bos, M. E. M.
Terwogt, J. M. Meerum
Linn, S. C.
Sonke, G. S.
[J]. CANCER RESEARCH, 2016, 76
[47] Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer
Cochereau, D.
Cottu, P.
[J]. ONCOLOGIE, 2015, 17 (04) : 194 - 196
[48] A randomized, controlled phase II trial of neoadjuvant ado-trastuzumab emtansine, lapatinib, and nab-paclitaxel versus trastuzumab, pertuzumab, and paclitaxel in HER2-positive breast cancer (TEAL study)
Patel, Tejal A.
Ensor, Joe E.
Creamer, Sarah L.
Boone, Toniva
Rodriguez, Angel A.
Niravath, Poly A.
Darcourt, Jorge G.
Meisel, Jane L.
Li, Xiaoxian
Zhao, Jing
Kuhn, John G.
Rosato, Roberto R.
Qian, Wei
Belcheva, Anna
Schwartz, Mary R.
Kaklamani, Virginia G.
Chang, Jenny C.
[J]. BREAST CANCER RESEARCH, 2019, 21 (01)
[49] Neoadjuvant pyrotinib plus trastuzumab and nab-paclitaxel for HER2-positive early or locally advanced breast cancer: an exploratory phase II trial
Zhong, Xiaorong
He, Ping
Chen, Jie
Yan, Xi
Wei, Bin
Zhang, Zhang
Bu, Hong
Li, Jing
Tian, Tinglun
Lv, Qing
Wang, Xiaodong
Li, Hongjiang
Wang, Jing
Huang, Juan
Suo, Jiaojiao
Liu, Xiaoxiao
Zheng, Hong
Luo, Ting
[J]. GLAND SURGERY, 2022, 11 (01) : 216 - +
[50] Adjuvant Paclitaxel and Trastuzumab for Node-Negative, HER2-Positive Breast Cancer
Tolaney, Sara M.
Barry, William T.
Dang, Chau T.
Yardley, Denise A.
Moy, Beverly
Marcom, P. Kelly
Albain, Kathy S.
Rugo, Hope S.
Ellis, Matthew
Shapira, Iuliana
Wolff, Antonio C.
Carey, Lisa A.
Overmoyer, Beth A.
Partridge, Ann H.
Guo, Hao
Hudis, Clifford A.
Krop, Ian E.
Burstein, Harold J.
Winer, Eric P.
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2015, 372 (02): : 134 - 141

← 1 2 3 4 5 →